The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Jeffrey M Ryckman; Bradley N Reames; Kelsey A Klute; William A Hall; Michael J Baine; May Abdel-Wahab; Chi Lin

doi:10.1016/j.ctro.2021.04.002

The timing and design of stereotactic radiotherapy approaches as a part of neoadjuvant therapy in pancreatic cancer: Is it time for change?

Clin Transl Radiat Oncol. 2021 Apr 19:28:124-128. doi: 10.1016/j.ctro.2021.04.002. eCollection 2021 May.

Authors

Jeffrey M Ryckman¹, Bradley N Reames², Kelsey A Klute³, William A Hall⁴, Michael J Baine⁵, May Abdel-Wahab⁶, Chi Lin⁵

Affiliations

¹ Department of Radiation Oncology, West Virginia University Cancer Institute, Parkersburg, WV, USA.
² Department of Surgery, University of Nebraska Medical Center, Omaha, NE, USA.
³ Department of Medical Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
⁴ Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
⁵ Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
⁶ Division of Human Health, International Atomic Energy Agency, Vienna, Austria.

Abstract

Stereotactic Radiotherapy (SRT) over 5-15 days can be interdigitated without delaying chemotherapy. Bridging chemotherapy may allow for extended intervals to surgery, potentially improving sterilization of surgical margins and overall survival. SRT for pancreatic adenocarcinoma should not be limited to the tumor, and should consider hypofractionated approaches to regional nodes.

Keywords: Pancreatic cancer; Stereotactic body radiotherapy; Total neoadjuvant therapy.

Publication types

Review